Evaluation of the performance of the microscan pos breakpoint combo panel type 28 for susceptibility testing of staphylococcus aureus: Low-range minimum inhibitory concentration of vancomycin, cefoxitin screening, and inducible clindamycin resistance detection

Korean Journal of Laboratory Medicine

Volumn 30, Issue 6, 2010, Pages 637-646

  Ji, Misuk ^a   Lee, Miyoung ^a   Noh, Sinae ^a   Kim, Mi Na ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Clindamycin resistance; MRSA; Staphylococcus aureus; Susceptibility test; Vancomycin resistance

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEFOXITIN; CLINDAMYCIN; MECA PROTEIN, STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; GENETICS; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CEFOXITIN; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 78651293965     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2010.30.6.637     Document Type: Article

References (31)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339: 520-32.
2. Schito GC. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 2006;12(S1):3-8.
3. Lee H, Yong D, Lee K, Hong SG, Kim EC, Jeong SH, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2004. Korean J Clin Microbiol 2005;8:66-73.
4. Kim JS, Kim HS, Song W, Cho HC, Lee KM, Kim EC Antimicrobial resistance profiles of Staphylococcus aureus isolated in 13 Korean hospitals. Korean J Lab Med 2004;24:223-9.
5. Lee H, Kim CK, Lee J, Lee SH, Ahn JY, Hong SG, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2005 and 2006. Korean J Clin Microbiol 2007;1059-69.
6. Sakoulas G, Gold HS, Venkataraman L, DeGirolami PC, Eliopoulos GM, Qian Q. Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol 2001;39:3946-51.
7. Junkins AD, Lockhart SR, Heilmann KP, Dohm CL, Von Stein DL, Winokur PL, et al. BD Phoenix and Vitek 2 detection of mecAmediated resistance in Staphylococcus aureus with cefoxitin. J Clin Microbiol 2009;47:2879-82.
8. Spanu T, Sanguinetti M, D'Inzeo T, Ciccaglione D, Romano L, Leone F, et al. Identification of methicillin-resistant isolates of Staphylococcus aureus and coagulase-negative staphylococci responsible for bloodstream infections with the Phoenix system. Diagn Microbiol Infect Dis 2004;48:221-7.
9. Yamazumi T, Marshall SA, Wilke WW, Diekema DJ, Pfaller MA, Jones RN. Comparison of the Vitek Gram-Positive Susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus. J Clin Microbiol 2001;39:53-6.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement, M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
11. Uh Y, Hwang GY, Jang IH, Kwon O, Yoon KJ, Kim HY. Distributions of macrolide-lincosamide-streptogramin B resistance phenotypes in clinical isolates of staphylococi. Korean J Clin Microbiol 2008;11:78-83.
12. Lim HS, Lee H, Roh KH, Yum JH, Yong D, Lee K, et al. Prevalence of inducible clindamycin resistance in staphylococcal isolates at a Korean tertiary care hospital. Yonsei Med J 2006;47:480-4.
13. Lewis JS 2nd and Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005;40:280-5.
14. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications, Clin Infect Dis 2002;34:482-92.
15. Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, McDougal LK, et al. Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wells. J Clin Microbiol 2007;45:3954-7.
16. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
17. Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:3861-70.
18. Tenover FC, Lancaster MV, Hill BC Steward CD, Stocker SA, Hancock GA, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7.
19. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
20. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
21. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. Casecontrol study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006;28:1208-16.
22. Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters: approved guideline. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2001.
23. Hanaki H, Hososaka Y, Yanagisawa C, Otsuka Y, Nagasawa Z, Nakae T, et al. Occurrence of vancomycm-intermediate-resistant Staphylococcus aureus in Japan. J Infect Chemother 2007;13:118-21.
24. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010;65:1015-8.
25. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6.
26. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008;32:378-85.
27. Swenson JM, Anderson KF, Lonsway DR, Thompson A, McAllister SK, Limbago BM, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009;47:2013-7.
28. Satola SW, Caliendo AM, Farley MM, Patel JB, Burd EM. Lack of heteroresistance among Staphylococcus aureus isolates with vancomycin MICs of 2 μg/mL by automated testing. J Clin Microbiol 2009;47:2680-1.
29. Webster D, Rennie RP, Brosnikoff CL, Chui L, Brown C. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada. Diagn Microbiol Infect Dis 2007;57:177-81.
30. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007;59:309-17.
31. Yun HJ, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003;51:619-23.